SCHEMBL3329611

SCHEMBL3329611

CCOC(=O)c1cc(C#N)c(=O)[nH]c1COCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.55
CDK5R1 Q15078 2/20 0.55
KDM4E B2RXH2 12/20 0.50
ALDH1A1 P00352 8/20 0.50
MAPT P10636 5/20 0.50
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
RXFP1 Q9HBX9 2/20 0.50
HSD17B10 Q99714 1/20 0.50
LMNA P02545 3/20 0.46
HPGD P15428 3/20 0.46
POLB P06746 2/20 0.46
GLA P06280 1/20 0.46
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 4/20 0.45
L3MBTL1 Q9Y468 4/20 0.45
NPSR1 Q6W5P4 3/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3226898 0.85 KMT2A (0.46) CDK5CDK5R1KDM4EALDH1A1MAPT
SCHEMBL5902061 0.83 GAA (0.61) CDK5CDK5R1KDM4EALDH1A1MAPT
SCHEMBL4105383 0.83 ALDH1A1 (0.52) KDM4EALDH1A1MAPTKMT2AMEN1
SCHEMBL5902230 0.83 CDK5 (0.55) CDK5CDK5R1KDM4EALDH1A1MAPT
SCHEMBL4105396 0.81 MAPT (0.58) CDK5CDK5R1KDM4EALDH1A1MAPT
SCHEMBL9449305 0.80 SMN1; SMN2 (0.47) CDK5CDK5R1KDM4EALDH1A1KMT2A
SCHEMBL22115166 0.80 MAPT (0.56) KDM4EALDH1A1MAPTKMT2AMEN1
SCHEMBL3326985 0.79 MAPT (0.55) KDM4EALDH1A1MAPTKMT2AMEN1
SCHEMBL26784496 0.79 KDM4E (0.56) CDK5CDK5R1KDM4EALDH1A1MAPT
SCHEMBL3587530 0.79 MAPT (0.55) KDM4EALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111303146-A 3-cyanopyridine compound, pharmaceutical composition containing same, preparation method and application thereof 中国科学院上海药物研究所 2020-06-19 CN disclosed
WO-2020119590-A1 3-CYANOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USES THEREOF. 中国科学院上海药物研究所 2020-06-18 WO disclosed
US-20100137277-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS ASTRAZENECA AB (SE) 2010-06-03 US disclosed
EP-2111400-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. AstraZeneca AB (SE) 2009-10-28 EP disclosed
US-20080171732-A1 New Pyridine Analogues IX 519 ASTRAZENECA AB (SE) 2008-07-17 US disclosed
WO-2008085117-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. ASTRAZENECA AB (SE) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171732-A1 New Pyridine Analogues IX 519 P2RY12, P2RY11, P2RY1 CDK5 1152/4885CDK5R1 774/4885KDM4E 3186/4885
US-20100137277-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS P2RY12, P2RY11, P2RY1 CDK5 1429/4885CDK5R1 1086/4885KDM4E 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.